Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Working Capital Changes (2020 - 2025)

Mirum Pharmaceuticals has reported Other Working Capital Changes over the past 6 years, most recently at -$6.0 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$6.0 million for Q4 2025, down 214.6% from a year ago — trailing twelve months through Dec 2025 was $5.8 million (up 836.06% YoY), and the annual figure for FY2025 was $5.8 million, up 836.06%.
  • Other Working Capital Changes for Q4 2025 was -$6.0 million at Mirum Pharmaceuticals, down from $10.4 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for MIRM hit a ceiling of $10.4 million in Q3 2025 and a floor of -$6.0 million in Q4 2025.
  • Median Other Working Capital Changes over the past 5 years was $127000.0 (2022), compared with a mean of $425600.0.
  • Peak annual rise in Other Working Capital Changes hit 4660.0% in 2024, while the deepest fall reached 319.18% in 2024.
  • Mirum Pharmaceuticals' Other Working Capital Changes stood at -$1.0 million in 2021, then surged by 416.91% to $3.2 million in 2022, then tumbled by 190.56% to -$2.9 million in 2023, then surged by 35.15% to -$1.9 million in 2024, then crashed by 214.6% to -$6.0 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$6.0 million (Q4 2025), $10.4 million (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.